secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122297
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports Q3 2024 net loss $88.1M; RLY-2608 shows 9.2-month median PFS
--------------------------------------------------------------------------------

- Net loss $88.1M ($0.63/share); revenue $0 vs $25.2M year ago (prior Genentech milestone).
- Cash $839.6M at Sep 30, 2024; expected to fund operations into H2 2027.
- RLY-2608 + fulvestrant interim data: 9.2-month median PFS, 33% ORR in heavily pre-treated PI3Kα-mutated breast cancer.
- Plan to initiate Phase 3 pivotal trial of RLY-2608 + fulvestrant in 2L breast cancer in 2025.
- Raised $230M in Sep 2024 follow-on; streamlined R&D with ~$50M annual savings, 15% workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/0000950170-24-122297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/rlay-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer